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Abstract: Unloading leads to skeletal muscle atrophy via the upregulation of MuRF-1 and MAFbx
E3-ligases expression. Reportedly, histone deacetylases (HDACs) 4 and 5 may regulate the expression
of MuRF1 and MAFbx. To examine the HDAC-dependent mechanisms involved in the control of
E3-ubiquitin ligases expression at the early stages of muscle unloading we used HDACs 4 and 5
inhibitor LMK-235 and HDAC 4 inhibitor Tasqinimod (Tq). Male Wistar rats were divided into four
groups (eight rats per group): nontreated control (C), three days of unloading/hindlimb suspension
(HS) and three days HS with HDACs inhibitor LMK-235 (HSLMK) or Tq (HSTq). Treatment with
LMK-235 diminished unloading-induced of MAFbx, myogenin (MYOG), ubiquitin and calpain-1
mRNA expression (p < 0.05). Tq administration had no effect on the expression of E3-ligases.
The mRNA expression of MuRF1 and MAFbx was significantly increased in both HS and HSTq
groups (1.5 and 4.0 folds, respectively; p < 0.05) when compared with the C group. It is concluded
that during three days of muscle unloading: (1) the HDACs 4 and 5 participate in the regulation of
MAFbx expression as well as the expression of MYOG, ubiquitin and calpain-1; (2) the inhibition of
HDAC 4 has no effect on MAFbx expression. Therefore, HDAC 5 is perhaps more important for the
regulation of MAFbx expression than HDAC 4.
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1. Introduction
There are very few studies focusing on the triggering mechanisms involved in the regulation of
protein degradation during the early stages of skeletal muscle unloading. A majority of the previous
studies evaluated the role of nuclear transcription factor FoxO phosphorylation in the regulation of
expression of the E3 ubiquitin ligases MAFbx and MuRF1 during unloading. Typically, activation of
the Akt/mTOR/p70S6k pathway was analyzed. Suppression of this pathway during muscle unloading
leads to the dephosphorylation and nuclear translocation of FoxO with subsequent activation of the
expression of E3 ubiquitin ligases [1,2]. In previous studies, we documented that during muscle
unloading increased expression of E3 ubiquitin ligases was accompanied by the activation of some
components of the Akt-FoxO pathway while other components were not changed [3,4]. This suggests
that some other pathways can regulate activation of the E3 ubiquitin ligases during unloading. Recent
studies suggest that HDACs can directly interact with and regulate the activation of transcription
factors [5–7].
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We examined whether these alternative mechanisms are working via HDACs 4 and 5 to regulate
the expression of E3 ubiquitin ligases during unloading. Specifically, we were interested in whether
HDACs 4 and 5 modulate the expression/activity of FoxO and MYOG. Both of these transcription factors
are known to play a critical role in the activation of E3 ligases during unloading. HDACs 4 and 5 belong
to the class IIa HDACs. They promote neurogenic muscle atrophy via the transcriptional repression of
Dach2 that is responsible for the inhibition of MYOG-dependent atrophy-induced genes [8,9]. Previous
studies reported that activation of E3 ubiquitin ligases and unloading-induced skeletal muscle atrophy
were diminished by treatment with the HDACs 4 and 5 inhibitor trichostatin A [10]. Nevertheless, the
mechanisms regulating the expression of E3 ubiquitin ligases during trichostatin A treatment are still
incompletely understood. Since trichostatin A inhibits both HDACs 4 and 5, it is not clear which of
these HDACs has the most significant effect on the expression of E3 ubiquitin ligases during unloading.
In this study, we used HDACs 4 and 5 inhibitor LMK-235 and specific HDAC 4 inhibitor Tasqinimod
(Tq) to evaluate the activation of the unloading-induced genes. Currently, there is no specific HDAC 5
inhibitor available. We used three days of unloading time point in our study since at this time there
is maximal activation of the E3 ubiquitin ligases MAFbx and MuRF1 in soleus muscle [11,12]. If our
hypothesis about different roles of HDACs 4 and 5 in unloading is correct, then the comparison of
LMK-235 and Tq inhibitors should reveal which of the two HDACs is the most important for the
regulation of MYOG, MAFbx and MuRF1 expression, as well as FoxO phosphorylation.
2. Results
2.1. Effect of HDAC Inhibitors on the Expression and Activity of HDACs 4 and 5
To test whether treatment with LMK-235 and Tq affected the activity of HDACs during three days
of unloading we evaluated the content of acetylated histone H3 in HS, HSMLK, Tq and C groups.
Acetylation of H3 was significantly higher in the soleus muscle of HSMLK and Tq rats when compared
with HS and C rats (Figure 1A). LMK-235 and Tq treatment significantly increased mRNA expression
of HDAC 4 when compared with HS and C groups (Figure 1B). The content of the nuclear fraction
of HDAC 5 was significantly decreased by unloading (Figure 1C). Treatment with LMK-235 had no
significant effect on the nuclear HDAC 5 content, while Tq showed a trend for the increase when
compared with the HS group (Figure 1C).
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Figure 1. Evaluation of acetylated histone H3 content (A), histone deacetylases (HDAC) 4 mRNA
expression (B) and HDAC 5 nuclear content (C) in soleus muscles of nontreated control rats (C), rats
after 3 days of unloading (HS), 3 days HS with LMK-265 inhibitor (HSLMK) or HS with Tq inhibitor
(HSTq). Values are normalized to the levels of total histone H3 (A) or Lamin B1 (C) in each sample.
Levels of HDAC 4 mRNA were normalized to the levels of GAPDH in each sample (B). n = 8. * indicates
a significant difference from the control, p < 0.05.
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2.2. Effect of HDAC Inhibitors on Skeletal Muscle Atrophy
After three days of unloading soleus muscle mass decreased by approximately 20% in all three
groups. In HS rats it was 74.5 ± 3.0 mg (p < 0.05), in HSLMK 72.8 ± 3.1 mg (p < 0.05), and in HSTq
73.0 ± 2.3 mg (p < 0.05), while in C rats it was 93.5 ± 2.4 mg. At the same time, there was a significant
difference in the mRNA expression of ubiquitin and calpain-1 between the groups (Figure 2A,B).
The expression of ubiquitin was significantly higher in the soleus muscle of HS rats when compared
with C rats (Figure 2A). LMK-235 and Tq treatment significantly augmented the unloading-induced
ubiquitin expression (Figure 2A). The mRNA expression of ubiquitin was not significantly different in
HSMLK and HSTq groups when compared with C.
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Figure 2. Evaluation of the ubiquitin (A), calpain-1 (B) and eEF2k (C) mRNA expression in soleus
muscles of nontreated control rats (C), rats after 3 days of unloading (HS), 3 days HS with LMK-265
inhibitor (HSLMK) or HS with Tq inhibitor (HSTq). Values are normalized to the levels of GAPDH
mRNA expression in each sample. n = 8. * indicates a significant difference from the control, p < 0.05;
# indicates a significant difference from the HS, p < 0.05.
Calpain-1 is calcium-activated proteinase involved in the degradation of myofibrillar proteins
during skeletal muscle atrophy [13]. The expression of calpain-1 was significantly increased after
skeletal muscle unloading (Figure 2B).Treatment with LMK-235 blocked the increase of calpain-1
mRNA expression during unloading (Figure 2B). At the same time, treatment with Tq showed a trend
for the increase of calpain-1 mRNA expression when compared with the HS group (Figure 2B).
Eukaryotic elongation factor 2 kinase (eEF2k) regulates protein synthesis and protein expression
of eEF2k was previously shown to be upregulated by seven days of unloading [14]. In the current study,
the mRNA expression of eEF2k was increased by unloading (Figure 2C). Treatment with LMK-235
diminished this increase, while Tq treatment had no statistically significant effect (Figure 2C).
It was previously reported that the expression of E3 ubiquitin ligases MAFbx and MuRF1 is
increased after three days of unloading [15]. In the current study, the mRNA expression of MAFbx and
MuRF1 was also significantly increased by unloading (Figure 3). Treatment with LMK-235 blocked
the upregulation of MAFbx mRNA expression, while Tq treatment had no effect (Figure 3A). Neither
LMK-235 nor Tq treatments had a significant effect on the MuRF1 mRNA expression (Figure 3B).
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2.3. Effect of HDAC Inhibitors on Transcription Factors Regulating Expression of MAFbx and MuRF1
FoxO3, MYOG and P300 are known regulators of MAFbx and MuRF1 expression during unloading
(Bodine an Baehr, 2014). The current study tested whe her HDACs 4 and 5 regulate the ctivity of
these transcription factors during unl ading. The content of ph sphorylated F xO3 was decreased in
the HS group when compared with C (Figure 4A). Treatment with LMK-235 and Tq had no statistically
significant effect on the content of phosphorylated FoxO3 during unloading (Figure 4A).
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Figure 4. Evaluation of phosphorylated FoxO3 conte t (A), P30 nucle tent (B) and MYOG mRNA
expression (C) in soleus muscles of nontreated control rats (C), rats fter 3 days f unloading (HS), 3
days HS with LMK-265 inhibitor (HSLMK) or HS with Tq inhibitor (HSTq). Values are normalized to
the levels of total FoxO3 protein (A) or Lamin B1 (B) in each sample. Levels of MYOG mRNA were
normalized to the levels of GAPDH in each sample (C). n = 8. * indicates a significant difference from
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The nuclear content of P300 was decreased after three days of soleus muscle unloading (Figure 4B).
Treatment with LMK-235 showed a trend for lesseni g this increase, while Tq treatment had no
statistically significant effect (Figure 4B).
The mRNA expression of MYOG was increased after three days of unloading (Figure 4C).
Treatment with LMK-235 blocked this increase (Figure 4C), while Tq treatment had no statistically
significant effect (Figure 4C).
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3. Discussion and Conclusions
Unloading results in skeletal muscle atrophy via activation of protein degradation and decrease
of protein synthesis [16,17]. E3 ubiquitin ligases MAFbx and MuRF1 play a significant role in this
process. In the current study, we evaluated whether HDACs 4 and 5 are involved in the regulation of
unloading-induced processes of muscle atrophy.
There was no significant effect of HDACs 4 and 5 inhibitor LMK-235 or HDAC 4 inhibitor Tq on
the unloading-induced soleus muscle atrophy in our study. Three days is a minimal time point for the
detection of muscle atrophy during unloading [18]. Previous studies reported attenuation of muscle
atrophy with HDACs 4 and 5 inhibitors after 14 days of unloading [10]. It is likely that at the later
stages of muscle unloading HDACs 4 and 5 play a larger role in the regulation of muscle atrophy when
compared with the early stages of unloading.
The ubiquitin–proteasome pathway regulates the degradation of sarcomeric proteins during
muscle atrophy [19]. During unloading the expression of ubiquitin is significantly increased [16].
Treatment with LMK-235 and Tq blocked the unloading-induced increase in the ubiquitin mRNA
expression in our study. Calpains are calcium-activated proteinase that can be the first step in the
initiation of protein ubiquitination leading to muscle atrophy during unloading. Some data suggest
that calpains and ubiquitin–proteasome pathways are not always synchronized during skeletal muscle
atrophy [20].
eEF2k regulates protein synthesis during muscle atrophy [21]. eEF2 kinase phosphorylates
eEF2k blocking its translocation into the nucleus. This leads to the inhibition of protein synthesis.
The expression of eEF2k was significantly increased in HS and HSTq groups suggesting that protein
synthesis was decreased in these two groups. Inhibition of HDACs 4 and 5 with LMK-235 diminished
eEF2k increase, indicating that impairment of protein synthesis might be reduced.
Treatment with LMK-235 and Tq significantly increased the expression of HDAC 4 during
unloading. This might be a feedback response to the inhibition of the HDAC activity and this confirms
the activity of LMK-235 and Tq inhibitors in the current study. The content of HDAC 5 in the
nucleus was decreased by muscle unloading in our experiments. It was previously reported that
protein kinase D 1 (PKD1) creates recognition sites for the phosphorylated 14-3-3 chaperon protein
on HDAC 5 [22]. Binding of 14-3-3 to HDAC 5 leads to the translocation of HDAC 5 out of the
nucleus. Similar processes might be involved in the decrease of HDAC 5 content in the HS group
in our study, but this requires further investigations. It is known that HDACs control the promoter
activity of genes coding for E3 ubiquitin ligases [23]. HDAC 5 can directly bind to transcription
factor EB (TFEB) and inhibit TFEB-mediated MuRF1 expression [22]. Currently, there is no HDAC
5–specific inhibitor. We used LMK-235 that inhibits both HDACs 4 and 5, as well as HDAC 4-specific
inhibitor Tq. The unloading-induced mRNA expression of MAFbx was blocked by LMK-235 but
not Tq in our experiments. Moresi and colleagues previously showed that skeletal muscle-specific
knockout of HDACs 4 and 5 in mice results in a significant decrease of denervation-induced MuRF1
and MAFbx expression [24]. At the same time, inhibition of HDACs 4 and 5 with trichostatin A during
14 days of muscle unloading diminished upregulation of MuRF1 expression but had no effect on
MAFbx expression [10]. Therefore, the data presented in the current study correlate with the previous
observations. We showed for the first time that HDACs 4 and 5 regulate MAFbx expression during
three days of muscle unloading. Based on our results, HDAC 5 and not HDAC 4 plays the most critical
role in the upregulation of MAFbx during unloading.
During muscle denervation, HDACs 4 and 5 regulate MuRF1 and MAFbx expression via
the expression of MYOG [24–26]. MYOG is a muscle-specific transcription factor involved in the
coordination of numerous processes in skeletal muscle, including prolonged muscle immobilization [27].
It was previously reported that MHYOG is upregulated during prolonged muscle immobilization [27].
MYOG can directly bind to MuRF1 and MAFbx promoters and upregulate expression of these
genes [24,25]. Blocking MYOG expression decreases denervation-induced MuRF1 and MAFbx
expression and prevents muscle atrophy [24]. Our study showed significant upregulation of MYOG in
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response to unloading. Treatment with LMK-235 blocked unloading-induced upregulation of MYOG,
while Tq treatment had no effect. Therefore, HDAC 5 plays a larger role in the MYOG-mediated
MAFbx expression during unloading.
In addition to HDACs 4/5–MYOG signaling, several other signaling pathways are known
to regulate the expression of MuRF1 and MAFbx during muscle atrophy [26]. For example,
PI3K-Akt-mTORC1-FoxOs signaling. FoxO3 can interact with the promoters of MuRF1 [16,28,29] and
MAFbx [16] and activate the expression of these genes. Class IIa HDACs can deacetylate and activate
FoxO transcription factors [30]. To test the activity of FoxO3 we evaluated its phosphorylation and
compared it to the level of MuRF1 and MAFbx expression. FoxO3 phosphorylation was decreased by
unloading. Treatment with Tq diminished unloading-induced decrease of FoxO3 phosphorylation,
while LMK-235 treatment had no effect. Changes in unloading-induced FoxO3 phosphorylation did
not correlate with the level of MuRF1 and MAFbx expression. It is unlikely that FoxO3 phosphorylation
is involved in HDACs 4/5-mediated effects on MuRF1 and MAFbx expression in our study.
HDACs play a critical role in the repression of gene transcription by histone deacetylation and
increasing chromatin condensation [31–33]. We evaluated the acetylation levels of the N-terminal
end of histone H3. Unloading-induced histone H3 acetylation was significantly diminished by the
treatment with both LMK-235 and Tq inhibitors. In addition to the regulation of gene transcription
through the regulation of histone acetylation, histone acetyltransferases (HATs) and HDACs regulate
gene transcription via acetylation/deacetylation of transcription factors [31]. It was previously reported
that HAT acetylates FoxO3 [34]. A decrease of HAT activity increases FoxO3 transcriptional activity,
while the increase of HAT activity interferes with nuclear translocation of FoxO3 and diminishes its
transcriptional activity towards target genes [34]. Similarly, the decrease of MAFbx expression during
muscle unloading in response to LMK-235 treatment might be mediated by FoxO3 acetylation and not
by FoxO3 phosphorylation/dephosphorylation.
FoxO3 transcriptional activity can be also regulated via acetylation by P300 [35]. P300 acetylates
FoxO3 diminishing its transcriptional activity and preventing nuclear localization [35]. It was previously
reported that a decrease of P300 activity during skeletal muscle denervation leads to the activation
of FoxO3 and increased expression of its target gene MAFbx [35]. Our study showed a decrease of
P300 nuclear content in HS and HSTq groups, while the P300 nuclear content in the HSLMK group
was similar to the control group. The expression of MuRF1 and MAFbx was also the highest in HS
and HSTq groups in our study. This supports our hypothesis that the LMK-235-mediated decrease of
MAFbx mRNA expression in our experiments might be regulated by the decrease of transcriptional
activity of FoxO3 due to its increased acetylation.
In conclusion, the current study showed that after three days of skeletal muscle unloading HDACs
4 and 5 regulate mRNA expression of MYOG, MAFbx, calpain-1 and ubiquitin. Treatment with specific
HDAC 4 inhibitor Tq affected only the ubiquitin mRNA expression. This suggests that HDAC 5 plays
a more significant role than HDAC 4 during unloading-induced skeletal muscle atrophy.
4. Materials and Methods
4.1. Ethical Approval
All animal experiments were performed at the Institute of Biomedical Problems, RAS, Russia.
All experiments were approved by the Committee on Bioethics of the Russian Academy of Sciences
(protocol 448; 03/28/2017). The experiments were performed in accordance with the internationally
accepted regulations and rules of biomedical ethics and comply with the principles and regulations
described by Grundy [36].
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4.2. Animal Procedures
Animals were kept at 22 ◦C in a light-controlled environment (12:12 h light–dark cycle) with
unlimited access to water and food. In the first set of experiments we optimized the doses of LMK-235
and Tq required for the inhibition of HDACs 4 and 5 during muscle unloading. Previous studies used
LMK-235 to inhibit HDACs 4 and 5, and Tq to inhibit HDAC 4 using mouse models [37] and cell
lines [38,39]. These inhibitors readily diffuse into cells. The degree of inhibition of HDACs 4 and 5
with LMK-235 and Tq during unloading can be evaluated based on the acetylation of histones.
To determine the optimal dose of LMK-235, 15 male Wistar rats (3 months old, 180–200 g body
weight) were randomly assigned to one of five groups (3 animals/group): nontreated control (C), three
days of hindlimb suspension/unloading with (HSLMK) or without (HS) HDACs 4 and 5 inhibitor
LMK-235 (#A4494, ApexBio, Boston, MA, USA) in the dose of 10, 20, and 30 mg/kg of body weight
per day. LMK-235 was dissolved in 2% solution of DMSO in normal saline solution and 200 µL were
injected intraperitoneally. Similarly, to determine the optimal dose of Tq 15 male Wistar rats (three
months old, 180-200 g body weight) were randomly assigned to one of five groups (3 animals/group):
nontreated control (C), three days of hindlimb suspension/unloading with (HSTq) or without (HS)
HDAC 4 inhibitor Tq (#A3860, ApexBio, USA) in the dose of 10, 20 and 30 mg/kg of body weight per
day. Tq was delivered orally with a small amount of food. We ensured that each rat consumed the entire
small piece of food provided with each treatment. The control animals received an intraperitoneal
injection of 2% solution of DMSO in normal saline solution (for LMK-235 control) or equal amounts of
similar food without inhibitor (Tq control).
The main experiments were performed after the optimal dose was established for both inhibitors.
For the LMK-235 optimal concentration was 20 mg/kg of body weight per day injected intraperitoneally.
For the Tq optimal concentration was 10 mg/kg of body weight per day delivered orally with a small
amount of food. Fifty-six male Wistar rats (180–200 g body weight) were randomly assigned to one of
four groups (8 animals/group): nontreated control (C), three days of hindlimb suspension/unloading
with (HSLMK) or without (HS) HDACs 4 and 5 inhibitor LMK-235 and HDACs 4 inhibitor Tq (HSTq).
At the end of the 3-day experiment, rats were euthanized by an overdose of 10% avertin solution
(Sigma-Aldrich Corp., St. Louis, MO, USA). Soleus muscle was immediately dissected from each rat,
weighed, divided into aliquots, frozen in liquid nitrogen, and stored at −85 ◦C for the analyses.
4.3. Hindlimb Suspension
For the hindlimb suspension, a traction method of noninvasive tail-casting procedure was used [40].
A swivel harness system incorporated into the casting materials and attached to a hook at the top of
the cage was used for the suspension. The hook was adjusted in a way that allowed only the forelimbs
of the animal to reach the floor of the cage while the hindlimbs were suspended. The body axis of the
rats was at a 45 angle to the cage floor. Rats were free to move around the cage using forelimbs to
consume food and water.
4.4. Protein Extraction and Western Blot Analysis
Total protein extracts were prepared from 400 µg of the frozen soleus muscle. To maintain extract
integrity and function Complete Protease Inhibitor Cocktail (#sc-29130, Santa Cruz Biotechnology,
Dallas, TX, USA), Phosphatase Inhibitor Cocktail B (#sc-45045, Santa Cruz Biotechnology, Dallas,
TX, USA), PMSF (1 mM), aprotinin (10 µg/mL), leupeptin (10 µg/mL), and pepstatin A (10 µg/mL)
were used. Cytoplasmic and nuclear fractions were isolated using NE-PER Nuclear and Cytoplasmic
Extraction Reagents (Thermo Scientific, Waltham, MA, USA). Quick Start Bradford Protein Assay
(Bio-Rad Laboratories, Hercules, CA, USA) was used to quantify protein content. The samples were
diluted in Laemmli buffer, run on 10% SDS-PAGE (20 µg/lane), and transferred to a nitrocellulose
membrane (Bio-Rad Laboratories, Hercules, CA, USA). After blocking with blocking buffer (5% nonfat
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milk powder, TBS pH 7.4, and 0.1% Tween-20) the membranes were incubated overnight at 4 ◦C with
the primary antibodies.
We used primary antibodies against total Akt (1:1000; #2920, Cell Signaling Technology, USA)
and phosphorylated Akt (Ser 473; 1:1500, 4058, Cell Signaling Technology, USA), total histone H3
(1:500, #9715, Cell Signaling Technology, Danvers, MA, USA) and acetylated histone H3 (1:500, #06-599,
Millipore, Burlington, MA, USA), total FoxO3 (1:1000; #2497, Cell Signaling Technology, Danvers,
MA, USA) and phosphorylated FoxO3 (Ser 253; 1:1000; #sc-101683, Santa Cruz Biotechnology, Dallas,
TX, USA), total HDAC 5 (1:3000, #ab1439, ABCAM, Cambridge, MA, USA), total HAT P300 (1:2000,
#ab231010, ABCAM, Cambridge, MA, USA). Blots incubated with antibodies against GAPDH (1:10,000,
#G041, Applied Biological Materials Inc., Richmond, BC, Canada) were used for the normalization
of the loading of cytoplasmic fractions. Lamin B1 content (1: 1000, #ab16048, ABCAM, Cambridge,
MA, USA) was used for the normalization of the loading of nuclear fractions. After three washes (10
min each) with TBS-Tween (TBS and 0.1% Tween-20), the membranes were incubated for one hour at
room temperature with horseradish peroxidase-conjugated goat anti-rabbit (1:30,000, #111-035-003,
Jackson Immuno Research, West Grove, PA, USA) or goat anti-mouse (1:20,000, #1706516, Bio-Rad,
Hercules, CA, USA) secondary antibodies. The membranes were washed again in TBS-Tween three
times, incubated with Clarity Western ECL Substrate (Bio-Rad Laboratories, Hercules, CA, USA). All
images were analyzed within the linear range. The protein bands were quantified using a C-DiGit Blot
Scanner (LI-COR Biotechnology, Lincoln, NE, USA) and Image Studio C-DiGit software. Total protein
staining (Ponceau S) was used for the control of loading. The protein expression data for each group
are expressed as a percentage of the control group values.
4.5. RNA Isolation and Reverse Transcription
Eighty micrograms of frozen soleus muscle were used for isolation of total RNA using RNeasy
Micro Kit (Qiagen, Hilden, Germany). RNA samples were treated with proteinase K and DNase I. RNA
concentration was evaluated using a NanoPhotometer (Implen GmbH, Munich, Germany). Isolated
RNA in aqueous solution was frozen at −85 ◦C for storage. Reverse transcription was performed by
incubating 0.5 µg of RNA, random hexamers d(N)6, dNTPs, RNase inhibitor, and MMLV (Moloney
Murine Leukemia Virus) reverse transcriptase (Moscow, Russia) for 60 min at 42 ◦C.
4.6. Quantitative PCR Analysis
One microliter of cDNA was amplified in a 25 µL SYBR Green PCR reaction containing 1×
Quantitect SYBR Green Master Mix (Syntol, Moscow, Russia) and 10 pM of each forward and reverse
primer. The sequences of the primers used in the current study are presented in Table 1. All primers
were synthesized by Syntol (Moscow, Russia). The optimal temperature for each PCR primer pair was
used for annealing. The amplification was monitored in real-time using an iQ5 Multicolor Real-Time
PCR Detection System (Bio-Rad Laboratories, Hercules, CA, USA). Melting curve analysis was used to
confirm the amplification specificity. Relative quantification was performed based on the threshold
cycle (CT value) for each PCR sample [41]. Initially, two housekeeping genes were evaluated for
normalization: GAPDH and β-actin. Normalizat‘1aaw aion of the level of expression of GAPDH and
β-actin showed similar results. GAPDH was chosen for the normalization of all quantitative PCR
analysis experiments in the current study.
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Table 1. Primers used for QRT-PCR study.
Gene Forward Primer Reverse Primer
β-actin 5′- TCATGAAGTGTGACGTTGACATCC -3′ 5′- GTAAAACGCAGCTCAGTAACAGTC -3′
Calpain-1 5′- CATGGCTAAGAGCAGGAAGG -3′ 5′- CGAAGTCTGCAGGTCTAGGG -3′
eEF2k 5′- AGAAGCTGGTGACAGGCAGT -3′ 5′- GGGTTCTTGTCCAGTCCAAA -3′
GAPDH 5′- ACGGCAAGTTCAACGGCACAGTCAA -3′ 5′- GCTTTCCAGAGGGGCCATCCACA -3′
HDAC 4 5′- CTACAACCACCCTGTCTTGG -3′ 5′-ATGCGGAGTCTGTAACATCC-3′
MAFbx 5′- CTACGATGTTGCAGCCAAGA -3′ 5′- GGCAGTCGAGAAGTCCAGTC -3′
MuRF1 5′- GCCAATTTGGTGCTTTTTGT -3′ 5′- AAATTCAGTCCTCTCCCCGT -3′
MYOG 5′- ACTCCCTTACGTCCATCGTG -3′ 5′- CAGGACAGCCCCACTTAAAA -3′
Ubiquitin 5′- CACCAAGAAGGTCAAACAGGA -3′ 5′- GCAAGAACTTTATTCAAAGTGCAA -3′
4.7. Statistical Analysis
All PCR data are expressed as the median and interquartile range (0.25–0.75). Statistical analysis
was performed using the REST 2009 v.2.0.12 (Qiagen, Hilden, Germany) and Origin Pro v.8.0 (OriginLab
Corp., Northampton, MA, USA) programs. All Western blot data are expressed as means ± SE.
Significant differences between groups were statistically analyzed using two-way ANOVA followed
by Tukey’s test. When normality testing failed, data were analyzed by nonparametric methods
(Kruskal–Wallis ANOVA followed by Dunnett’s test). Differences with values of p < 0.05 were
considered statistically significant.
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